Seattle biotech Achieve Life Sciences on Tuesday announced an experimental drug meant to help people quit smoking did exactly that in a clinical trial, paving the way for the company to seek approval for a product that would face stiff competition.
In the study, dubbed ORCA-3, participants took either the smoking cessation drug cytisinicline or a placebo pill three times a day for six or 12 weeks. About 30% of those on a 12-week course of cytisinicline went the last month of treatment without smoking, compared to 9.4% of participants in the placebo group. And nearly 15% of smokers on a six-week course of cytisinicline quit during the last month of treatment, compared to 6% of those on placebo. Both of these differences were statistically significant, and the drug’s side effects were relatively mild.
It’s the second time the company has reported Phase 3 trial results showing…
Click here to view original post